GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Natural Capsules Ltd

Natural Biogenex Approves Rights Issue of Rs. 1.11 Crore Equity Shares

FUNDRAISE ▲ Positive Development LOW RISK
📅 Filed on BSE: 27 May 2026, 09:30 PM IST  ·  BSE ID: 571b0ecd-94dc-4459-9b17-9e088024b34a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's subsidiary is raising funds by offering new shares to its existing shareholders at a fixed price.
🤖 AI Summary
  • Material subsidiary Natural Biogenex approved rights issue of 11,11,200 equity shares.
  • Rights issue is for cash at par, with each share priced at ₹10.
  • Total funds to be raised by the subsidiary amount to ₹1,11,12,000.
  • The Board Meeting for this approval was held on May 27, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Rights Issue Size
11,11,200 Equity Shares
Issue Price
₹10 per share
Total Funds Raised
₹1,11,12,000
Board Meeting Date
May 27, 2026
🏢 How This Affects the Company
📈
Business Impact
This rights issue by the material subsidiary will provide capital for its operations or expansion plans, indirectly impacting Natural Capsules Ltd's overall group strategy.
💰
Financial Impact
The subsidiary's equity base will increase by ₹1,11,12,000, potentially strengthening its balance sheet and financing capacity.
⚙️
Operational Impact
Funds raised may be deployed for enhancing operational capacity or pursuing new business initiatives within the subsidiary.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from Natural Capsules Ltd shareholders based on this filing; the decision pertains to the subsidiary.
👤
Who Is Affected
Shareholders of Natural Biogenex Private Limited will be the direct recipients of the rights issue offering. Natural Capsules Ltd shareholders will be indirectly affected.
🔍
Management Signal
Management is utilizing subsidiary-level rights issues to inject capital, indicating a focus on strengthening the subsidiary's financial position.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Announcement of the detailed terms and record date for the rights issue.
Subsequent filings on the subscription status and allotment of rights shares.
Updates on the utilization of funds raised by Natural Biogenex.
LOW RISK Subsidiary board approval for a rights issue is a standard corporate finance action.
💡 Investor Takeaway
Natural Biogenex Private Limited, a material subsidiary, approved a rights issue of 11,11,200 equity shares at ₹10 each, aiming to raise ₹1,11,12,000.
⚖️ Strengths & Concerns

✅ Positives

  • Material subsidiary successfully secured Board approval for a rights issue, signaling capital raising initiative.
  • Rights issue priced at par (₹10 per share) provides a clear valuation basis for new equity.
❓ Frequently Asked Questions
What has Natural Biogenex Private Limited approved?
Natural Biogenex Private Limited has approved a rights issue of 11,11,200 equity shares at ₹10 each.
How much capital will Natural Biogenex raise through the rights issue?
The rights issue is expected to raise ₹1,11,12,000 in total.
When was the decision for the rights issue made?
The decision was made at the Board Meeting of Natural Biogenex held on May 27, 2026.
What is the issue price of the equity shares in the rights issue?
The equity shares will be issued at ₹10 per share, for cash at par.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.